Patents by Inventor Natalya D. Bodyak
Natalya D. Bodyak has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11964025Abstract: The present disclosure relates generally to antibody-drug conjugates comprising peptide-containing linkers and to methods of using these conjugates as therapeutics and/or diagnostics. Also disclosed herein are peptide-containing scaffolds useful to conjugate with a targeting moiety (e.g., an antibody), a drug, or both to produce the antibody-drug conjugates.Type: GrantFiled: August 12, 2021Date of Patent: April 23, 2024Assignee: Mersana Therapeutics, Inc.Inventors: Aleksandr V. Yurkovetskiy, Natalya D. Bodyak, Bingfan Du, Dmitry R. Gumerov, Mariya Kozytska, Timothy B. Lowinger, Cheri A. Stevenson, Mao Yin
-
Publication number: 20230265197Abstract: This invention provides fully human monoclonal antibodies that recognize HER2. The invention further provides methods of using such monoclonal antibodies in a variety of therapeutic, diagnostic, and prophylactic indications.Type: ApplicationFiled: October 26, 2022Publication date: August 24, 2023Inventors: Natalya D. BODYAK, Michael J. DEVIT, Eric M. KRAULAND, Timothy B. LOWINGER, Peter U. PARK, Bianka PRINZ, Aleksandr V. YURKOVETSKIY
-
Publication number: 20230043447Abstract: The present disclosure relates generally to antibody-drug conjugates comprising peptide-containing linkers and to methods of using these conjugates as therapeutics and/or diagnostics. Also disclosed herein are peptide-containing scaffolds useful to conjugate with a targeting moiety (e.g., an antibody), a drug, or both to produce the antibody-drug conjugates.Type: ApplicationFiled: August 12, 2021Publication date: February 9, 2023Inventors: Aleksandr V. YURKOVETSKIY, Natalya D. BODYAK, Bingfan DU, Dmitry R. GUMEROV, Mariya KOZYTSKA, Timothy B. LOWINGER, Cheri A. STEVENSON, Mao YIN
-
Patent number: 11518812Abstract: This invention provides fully human monoclonal antibodies that recognize HER2. The invention further provides methods of using such monoclonal antibodies in a variety of therapeutic, diagnostic, and prophylactic indications.Type: GrantFiled: October 2, 2019Date of Patent: December 6, 2022Assignee: Mersana Therapeutics, Inc.Inventors: Natalya D. Bodyak, Michael J. DeVit, Eric M. Krauland, Timothy B. Lowinger, Peter U. Park, Bianka Prinz, Aleksandr V. Yurkovetskiy
-
Patent number: 11135307Abstract: The present disclosure relates generally to antibody-drug conjugates comprising peptide-containing linkers and to methods of using these conjugates as therapeutics and/or diagnostics. Also disclosed herein are peptide-containing scaffolds useful to conjugate with a targeting moiety (e.g., an antibody), a drug, or both to produce the antibody-drug conjugates.Type: GrantFiled: November 21, 2017Date of Patent: October 5, 2021Assignee: Mersana Therapeutics, Inc.Inventors: Aleksandr V. Yurkovetskiy, Natalya D. Bodyak, Bingfan Du, Dmitry R. Gumerov, Mariya Kozytska, Timothy B. Lowinger, Cheri A. Stevenson, Mao Yin
-
Publication number: 20210301031Abstract: This disclosure provides NaPi2b-targeted antibody-drug conjugates (e.g., NaPi2b-targeted antibody-polymer-drug conjugates) that specifically bind to the extracellular region of SLC34A2, and to methods of using such conjugates in a variety of therapeutic, diagnostic, and prophylactic indications.Type: ApplicationFiled: January 20, 2021Publication date: September 30, 2021Inventors: Donald A. BERGSTROM, Natalya D. BODYAK, Timothy B. LOWINGER, Peter U. PARK, Laura L. POLING, Aleksandr V. YURKOVETSKIY
-
Publication number: 20210106690Abstract: A drug conjugate is provided herein. The conjugate comprises a protein based recognition-molecule (PBRM) and a polymeric carrier substituted with one or more -LD-D, the protein based recognition-molecule being connected to the polymeric carrier by LP. Each occurrence of D is independently a therapeutic agent having a molecular weight ?5 kDa. LD and LP are linkers connecting the therapeutic agent and PBRM to the polymeric carrier respectively. Also disclosed are polymeric scaffolds useful for conjugating with a PBRM to form a polymer-drug-PBRM conjugate described herein, compositions comprising the conjugates, methods of their preparation, and methods of treating various disorders with the conjugates or their compositions.Type: ApplicationFiled: January 23, 2020Publication date: April 15, 2021Inventors: Aleksandr V. YURKOVETSKIY, Mao YIN, Timothy B. LOWINGER, Joshua D. THOMAS, Charles E. HAMMOND, Cheri A. STEVENSON, Natalya D. BODYAK, Patrick R. CONLON, Dmitry R. GUMEROV
-
Patent number: 10947317Abstract: This disclosure provides NaPi2b-targeted antibody-drug conjugates (e.g., NaPi2b-targeted antibody-polymer-drug conjugates) that specifically bind to the extracellular region of SLC34A2, and to methods of using such conjugates in a variety of therapeutic, diagnostic, and prophylactic indications.Type: GrantFiled: March 13, 2017Date of Patent: March 16, 2021Assignee: Mersana Therapeutics, Inc.Inventors: Donald A. Bergstrom, Natalya D. Bodyak, Timothy B. Lowinger, Peter U. Park, Laura L. Poling, Aleksandr V. Yurkovetskiy
-
Patent number: 10603386Abstract: A drug conjugate is provided herein. The conjugate comprises a protein based recognition-molecule (PBRM) and a polymeric carrier substituted with one or more -LD-D, the protein based recognition-molecule being connected to the polymeric carrier by LP. Each occurrence of D is independently a therapeutic agent having a molecular weight?5 kDa. LD and LP are linkers connecting the therapeutic agent and PBRM to the polymeric carrier respectively. Also disclosed are polymeric scaffolds useful for conjugating with a PBRM to form a polymer-drug-PBRM conjugate described herein, compositions comprising the conjugates, methods of their preparation, and methods of treating various disorders with the conjugates or their compositions.Type: GrantFiled: August 22, 2017Date of Patent: March 31, 2020Assignee: Mersana Therapeutics, Inc.Inventors: Aleksandr V. Yurkovetskiy, Mao Yin, Timothy B. Lowinger, Joshua D. Thomas, Charles E. Hammond, Cheri A. Stevenson, Natalya D. Bodyak, Patrick R. Conlon, Dmitry R. Gumerov
-
Publication number: 20200031941Abstract: This invention provides fully human monoclonal antibodies that recognize HER2. The invention further provides methods of using such monoclonal antibodies in a variety of therapeutic, diagnostic, and prophylactic indications.Type: ApplicationFiled: October 2, 2019Publication date: January 30, 2020Inventors: Natalya D. BODYAK, Michael J. DeVIT, Eric M. KRAULAND, Timothy B. LOWINGER, Peter U. PARK, Bianka PRINZ, Aleksandr V. YURKOVETSKIY
-
Patent number: 10537645Abstract: Auristatin compounds and conjugates thereof are provided herein. The conjugate comprises a protein based recognition-molecule (PBRM) and a polymeric carrier substituted with one or more -LD-D, the protein based recognition-molecule being connected to the polymeric carrier by LP. Each occurrence of D is independently an Auristatin compound. LD and LP are linkers connecting the therapeutic agent and PBRM to the polymeric carrier respectively. Also disclosed are polymeric scaffolds useful for conjugating with a PBRM to form a polymer-drug-PBRM conjugate described herein, compositions comprising the conjugates, methods of their preparation, and methods of treating various disorders with the conjugates or their compositions.Type: GrantFiled: February 22, 2018Date of Patent: January 21, 2020Assignee: Mersana Therapeutics, Inc.Inventors: Aleksandr V. Yurkovetskiy, Mao Yin, Timothy B. Lowinger, Joshua D. Thomas, Charles E. Hammond, Cheri A. Stevenson, Natalya D. Bodyak, Patrick R. Conlon, Dmitry R. Gumerov
-
Publication number: 20180271996Abstract: Disclose herein are combinations comprising HER2-targeted antibody-drug conjugates and immune checkpoint inhibitors and methods of using such combinations in a variety of therapeutic, diagnostic, and prophylactic indications.Type: ApplicationFiled: February 27, 2018Publication date: September 27, 2018Applicants: Mersana Therapeutics, Inc., Millennium Pharmaceuticals Inc.Inventors: Natalya D. BODYAK, Donald A. BERGSTROM, Marc HYER, Timothy B. LOWINGER, Marina PROTOPOPOVA, Ole Petter VEIBY, Aleksandr V. YURKOVETSKIY, Qing Xiu ZHANG
-
Publication number: 20180243428Abstract: Auristatin compounds and conjugates thereof are provided herein. The conjugate comprises a protein based recognition-molecule (PBRM) and a polymeric carrier substituted with one or more -LD-D, the protein based recognition-molecule being connected to the polymeric carrier by LP. Each occurrence of D is independently an Auristatin compound. LD and LP are linkers connecting the therapeutic agent and PBRM to the polymeric carrier respectively. Also disclosed are polymeric scaffolds useful for conjugating with a PBRM to form a polymer-drug-PBRM conjugate described herein, compositions comprising the conjugates, methods of their preparation, and methods of treating various disorders with the conjugates or their compositions.Type: ApplicationFiled: February 22, 2018Publication date: August 30, 2018Inventors: Aleksandr V. YURKOVETSKIY, Mao YIN, Timothy B. LOWINGER, Joshua D. THOMAS, Charles E. HAMMOND, Cheri A. STEVENSON, Natalya D. BODYAK, Patrick R. CONLON, Dmitry R. GUMEROV
-
Publication number: 20180154018Abstract: The present disclosure relates generally to antibody-drug conjugates comprising peptide-containing linkers and to methods of using these conjugates as therapeutics and/or diagnostics. Also disclosed herein are peptide-containing scaffolds useful to conjugate with a targeting moiety (e.g., an antibody), a drug, or both to produce the antibody-drug conjugates.Type: ApplicationFiled: November 21, 2017Publication date: June 7, 2018Inventors: Aleksandr V. YURKOVETSKIY, Natalya D. BODYAK, Bingfan DU, Dmitry R. GUMEROV, Mariya KOZYTSKA, Timothy B. LOWINGER, Cheri A. STEVENSON, Mao YIN
-
Patent number: 9943609Abstract: Auristatin compounds and conjugates thereof are provided herein. The conjugate comprises a protein based recognition-molecule (PBRM) and a polymeric carrier substituted with one or more -LD-D, the protein based recognition-molecule being connected to the polymeric carrier by LP. Each occurrence of D is independently an Auristatin compound. LD and LP are linkers connecting the therapeutic agent and PBRM to the polymeric carrier respectively. Also disclosed are polymeric scaffolds useful for conjugating with a PBRM to form a polymer-drug-PBRM conjugate described herein, compositions comprising the conjugates, methods of their preparation, and methods of treating various disorders with the conjugates or their compositions.Type: GrantFiled: January 19, 2016Date of Patent: April 17, 2018Assignee: Mersana Therapeutics, Inc.Inventors: Aleksandr V. Yurkovetskiy, Mao Yin, Timothy B. Lowinger, Joshua D. Thomas, Charles E. Hammond, Cheri A. Stevenson, Natalya D. Bodyak, Patrick R. Conlon, Dimitry R. Gumerov
-
Publication number: 20170348424Abstract: A drug conjugate is provided herein. The conjugate comprises a protein based recognition-molecule (PBRM) and a polymeric carrier substituted with one or more -LD-D, the protein based recognition-molecule being connected to the polymeric carrier by LP. Each occurrence of D is independently a therapeutic agent having a molecular weight ?5 kDa. LD and LP are linkers connecting the therapeutic agent and PBRM to the polymeric carrier respectively. Also disclosed are polymeric scaffolds useful for conjugating with a PBRM to form a polymer-drug-PBRM conjugate described herein, compositions comprising the conjugates, methods of their preparation, and methods of treating various disorders with the conjugates or their compositions.Type: ApplicationFiled: August 22, 2017Publication date: December 7, 2017Inventors: Aleksandr V. YURKOVETSKIY, Mao YIN, Timothy B. LOWINGER, Joshua D. THOMAS, Charles E. HAMMOND, Cheri A. STEVENSON, Natalya D. BODYAK, Patrick R. CONLON, Dmitry R. GUMEROV
-
Patent number: 9808528Abstract: A polymeric scaffold useful for conjugating with a protein based recognition-molecule (PBRM) to form a PBRM-polymer-drug conjugate is described herein. The scaffold includes one or more terminal maleimido groups. Also disclosed is a PBRM-polymer-drug conjugate prepared from the scaffold. Compositions comprising the conjugates, methods of their preparation, and methods of treating various disorders, such as cancer in a subject having low HER2 expression with the conjugates or their compositions are also described.Type: GrantFiled: June 18, 2015Date of Patent: November 7, 2017Assignee: Mersana Therapeutics, Inc.Inventors: Natalya D. Bodyak, Timothy B. Lowinger, Peter U. Park, Aleksandr V. Yurkovetskiy
-
Publication number: 20170313778Abstract: This invention provides fully human monoclonal antibodies that recognize HER2. The invention further provides methods of using such monoclonal antibodies in a variety of therapeutic, diagnostic, and prophylactic indications.Type: ApplicationFiled: July 14, 2017Publication date: November 2, 2017Inventors: Natalya D. BODYAK, Michael J. DeVIT, Eric M. KRAULAND, Timothy B. LOWINGER, Peter U. PARK, Bianka PRINZ, Aleksandr V. YURKOVETSKIY
-
Patent number: 9770519Abstract: A drug conjugate is provided herein. The conjugate comprises a protein based recognition-molecule (PBRM) and a polymeric carrier substituted with one or more -LD-D, the protein based recognition-molecule being connected to the polymeric carrier by LP. Each occurrence of D is independently a therapeutic agent having a molecular weight ?5 kDa. LD and LP are linkers connecting the therapeutic agent and PBRM to the polymeric carrier respectively. Also disclosed are polymeric scaffolds useful for conjugating with a PBRM to form a polymer-drug-PBRM conjugate described herein, compositions comprising the conjugates, methods of their preparation, and methods of treating various disorders with the conjugates or their compositions.Type: GrantFiled: August 24, 2015Date of Patent: September 26, 2017Assignee: Mersana Therapeutics, Inc.Inventors: Aleksandr Yurkovetskiy, Mao Yin, Timothy B. Lowinger, Joshua D. Thomas, Charles E. Hammond, Cheri A. Stevenson, Natalya D. Bodyak, Patrick R. Conlon, Dmitry R. Gumerov
-
Publication number: 20170266311Abstract: This disclosure provides NaPi2b-targeted antibody-drug conjugates (e.g., NaPi2b-targeted antibody-polymer-drug conjugates) that specifically bind to the extracellular region of SLC34A2, and to methods of using such conjugates in a variety of therapeutic, diagnostic, and prophylactic indications.Type: ApplicationFiled: March 13, 2017Publication date: September 21, 2017Inventors: Donald A. BERGSTROM, Natalya D. BODYAK, Timothy B. LOWINGER, Peter U. PARK, Laura L. POLING, Aleksandr V. YURKOVETSKIY